
Early diagnosis and treatment of feline osteoarthritis (OA) can give cats their best life back.

Feline OA is a quiet epidemic that is often underdiagnosed¹





4 measures you can take to help recognise and treat OA in more cats



Make sure cat owners understand the types of behaviour changes associated with feline OA pain and what should warrant a visit to the vet

CAT OWNERS ARE MISTAKING THE FOLLOWING SIGNS OF FELINE OA WITH AGEING³









Sensitive to touch





Decreased grooming



...and even if cat owners are recognising the above behaviours, they **aren't perceiving them as painful** to their beloved cat³







When cat owners have a **confirmed OA diagnosis**, they are more likely to **understand their cat is in pain** and follow your treatment recommendations³



OWNERS TURN TO AND TRUST VETERINARIANS AS THEIR #1 SOURCE OF INFORMATION³





85% of cat owners did not find taking their cat to the vet burdensome⁷

Feline OA can't be stopped, but if identified and treated earlier, both cat owners and cats experience relief

Cat owners just want what's best for their cats, and to improve their cat's quality of life, they are willing to:⁷



86%

of pet owners were willing to initiate a treatment for their cat with OA and


61%

would pay more to ensure their cat has an improved quality of life⁷



What are owners prepared to pay to manage their cats OA pain?

When price was presented, half of the pet owners STILL preferred Solensia^{®7}





50%

of all pet owners surveyed highlighted that they would prefer the profile of Solensia[®] at \$140.61 per month, over the Standard of Care (SoC) at \$53.40 per month, despite the increased price⁷

Thus,

of all pet owners surveyed appeared to value the improvements associated with the Solensia® profile despite the additional cost⁷



THE FIRST AND ONLY MONTHLY INJECTABLE ANTIBODY THERAPY FOR CATS WITH OSTEOARTHRITIS



Innovative Monthly Injection Works differently to NSAIDs by specifically targeting Nerve Growth Factor (NGF), a key player in OA pain⁸



Monoclonal Antibody Technology Minimal impact on the liver, kidneys and GIT⁹



Mobility

Increases mobility and decreases pain after the first injection¹⁰

Reducing pain helps to improve life quality¹¹



zoetis.com.au

1. Enomoto M, *et al. J Feline Med Surg* 2020;22(12):1137-1147. 2. Foster Rosenblatt Zoetis Anti-NGF data on file. May 2019. 3. Fulcrum Research Group: Osteoarthritis Cat Owner Journey 2020. 4. Zoetis Project November Veterinarian, April 2018. 5. Epstein M, *et al. J Fel Med Surg*. 2015;17:251-272. 6. Marino CL, *et al. J Feline Med Surg* 2014;16:465-472. 7. Feline OA-Willingness to PayPet Owner' Willingness To Pay For Therapy Outcomes In Feline Pain Associated With Osteoarthritis. 8. Epstein ME. *Vet Rec.* 2019;184(1):20-22. 9. Keizer RJ, *et al.* Clinical pharmacokinetics of therapeutic monoclonal antibodies. *Clin Pharmacokinet*. 2010;49(8):493-507. 10. Gruen ME, *et al. J Vet Intern Med*. 2016;30(4):1138-1148. 11. Reid J, *et al.* 2018;236(6):72-79.

Zoetis Australia Pty Ltd. Level 6, 5 Rider Boulevard, Rhodes NSW 2138. © 2022 Zoetis Inc. All rights reserved. June 2022. MM-19188. 2001288.